$48.25
+0.73
(+1.54%)▲
In the last 1 year, Haleon Plc Spon Ads has given 38.0% return, outperforming this stock by 80.9%
1.39%
Downside
Day's Volatility :3.2%
Upside
1.84%
34.82%
Downside
52 Weeks Volatility :64.93%
Upside
46.2%
Period | Catalent, Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 9.27% | 0.0% | 0.8% |
6 Months | -28.84% | 3.0% | 10.0% |
1 Year | -42.85% | 7.2% | 16.2% |
3 Years | -44.45% | 27.5% | 34.2% |
Market Capitalization | 8.5B |
Book Value | $25.61 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.3 |
PEG Ratio | 1.18 |
Wall Street Target Price | 51.29 |
Profit Margin | -5.43% |
Operating Margin TTM | 1.71% |
Return On Assets TTM | 0.43% |
Return On Equity TTM | -4.93% |
Revenue TTM | 4.3B |
Revenue Per Share TTM | 23.62 |
Quarterly Revenue Growth YOY | -17.0% |
Gross Profit TTM | 1.1B |
EBITDA | 495.0M |
Diluted Eps TTM | -1.3 |
Quarterly Earnings Growth YOY | -0.15 |
EPS Estimate Current Year | 1.01 |
EPS Estimate Next Year | 1.14 |
EPS Estimate Current Quarter | 0.1 |
EPS Estimate Next Quarter | 0.08 |
What analysts predicted
Upside of 6.3%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.5B | ↑ 18.7% |
Net Income | 83.6M | ↓ 23.86% |
Net Profit Margin | 3.39% | ↓ 1.9% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.5B | ↑ 2.22% |
Net Income | 132.0M | ↑ 57.89% |
Net Profit Margin | 5.24% | ↑ 1.85% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.1B | ↑ 22.89% |
Net Income | 220.7M | ↑ 67.2% |
Net Profit Margin | 7.13% | ↑ 1.89% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 4.0B | ↑ 29.21% |
Net Income | 585.0M | ↑ 165.07% |
Net Profit Margin | 14.63% | ↑ 7.5% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 4.8B | ↑ 20.76% |
Net Income | 519.0M | ↓ 11.28% |
Net Profit Margin | 10.75% | ↓ 3.88% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.8B | ↓ 0.54% |
Net Income | 499.0M | ↓ 3.85% |
Net Profit Margin | 10.39% | ↓ 0.36% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3B | ↑ 4.6% |
Net Income | 141.0M | ↑ 45.36% |
Net Profit Margin | 11.08% | ↑ 3.11% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3B | ↑ 3.14% |
Net Income | 188.0M | ↑ 33.33% |
Net Profit Margin | 14.32% | ↑ 3.24% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 22.16% |
Net Income | 0.0 | ↓ 100.0% |
Net Profit Margin | 0.0% | ↓ 14.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 12.43% |
Net Income | 81.0M | - |
Net Profit Margin | 7.05% | ↑ 7.05% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 9.75% |
Net Income | -227.0M | ↓ 380.25% |
Net Profit Margin | -21.89% | ↓ 28.94% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 2.99% |
Net Income | -86.0M | ↓ 62.11% |
Net Profit Margin | -8.05% | ↑ 13.84% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 4.5B | ↑ 31.17% |
Total Liabilities | 3.4B | ↑ 26.13% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 6.2B | ↑ 36.48% |
Total Liabilities | 4.5B | ↑ 30.72% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 7.8B | ↑ 25.75% |
Total Liabilities | 4.3B | ↓ 5.14% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 9.1B | ↑ 17.17% |
Total Liabilities | 4.8B | ↑ 13.27% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 10.5B | ↑ 15.31% |
Total Liabilities | 5.7B | ↑ 18.07% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 10.5B | ↑ 0.01% |
Total Liabilities | 5.7B | ↑ 0.37% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.3B | ↑ 1.17% |
Total Liabilities | 5.7B | ↓ 0.56% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.5B | ↑ 1.79% |
Total Liabilities | 5.7B | ↑ 0.39% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.2B | ↓ 2.87% |
Total Liabilities | 5.5B | ↓ 3.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.1B | ↑ 9.23% |
Total Liabilities | 6.2B | ↑ 13.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↓ 2.84% |
Total Liabilities | 6.1B | ↓ 1.73% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↓ 0.44% |
Total Liabilities | 6.1B | ↑ 0.33% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 374.5M | ↑ 25.04% |
Investing Cash Flow | -919.3M | ↑ 197.51% |
Financing Cash Flow | 669.1M | ↑ 314.82% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 247.7M | ↓ 33.86% |
Investing Cash Flow | -1.5B | ↑ 64.3% |
Financing Cash Flow | 1.2B | ↑ 79.55% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 440.3M | ↑ 77.76% |
Investing Cash Flow | -827.5M | ↓ 45.21% |
Financing Cash Flow | 1.0B | ↓ 16.62% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 433.0M | ↓ 1.66% |
Investing Cash Flow | -649.0M | ↓ 21.57% |
Financing Cash Flow | 142.0M | ↓ 85.82% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 439.0M | ↑ 1.39% |
Investing Cash Flow | -1.9B | ↑ 190.29% |
Financing Cash Flow | 1.0B | ↑ 626.06% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 439.0M | ↑ 0.0% |
Investing Cash Flow | -1.9B | ↑ 0.0% |
Financing Cash Flow | 1.0B | ↑ 0.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 138.0M | ↑ 100.0% |
Investing Cash Flow | -191.0M | ↓ 83.13% |
Financing Cash Flow | -3.0M | ↓ 93.88% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 69.0M | ↓ 50.0% |
Investing Cash Flow | -394.0M | ↑ 106.28% |
Financing Cash Flow | 1000.0K | ↓ 133.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -92.0M | ↓ 233.33% |
Investing Cash Flow | -116.0M | ↓ 70.56% |
Financing Cash Flow | 74.0M | ↑ 7300.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 214.0M | ↓ 332.61% |
Investing Cash Flow | -608.0M | ↑ 424.14% |
Financing Cash Flow | 523.0M | ↑ 606.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -64.0M | ↓ 129.91% |
Investing Cash Flow | -110.0M | ↓ 81.91% |
Financing Cash Flow | -25.0M | ↓ 104.78% |
Sell
Neutral
Buy
Catalent, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Catalent, Inc. | 4.67% | -28.84% | -42.85% | -44.45% | 11.42% |
![]() Neurocrine Biosciences Inc. | 5.98% | 19.04% | 8.68% | 15.61% | -4.03% |
![]() Haleon Plc Spon Ads | -1.57% | 1.59% | 37.97% | 9.85% | 9.85% |
![]() Zoetis Inc. | 0.65% | 9.47% | 20.33% | 13.05% | 102.58% |
![]() Viatris Inc. | -12.18% | 2.38% | 9.4% | -39.47% | -39.47% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Catalent, Inc. | 211.02 | NA | 1.18 | 1.01 | -0.05 | 0.0 | 0.0 | 25.61 |
![]() Neurocrine Biosciences Inc. | 63.98 | 63.98 | 1.87 | 2.35 | 0.11 | 0.08 | 0.0 | 18.99 |
![]() Haleon Plc Spon Ads | 23.82 | 23.82 | NA | 0.0 | 0.06 | 0.04 | 0.01 | 3.56 |
![]() Zoetis Inc. | 38.47 | 38.47 | 3.53 | 5.44 | 0.48 | 0.14 | 0.01 | 10.04 |
![]() Viatris Inc. | 7.07 | 7.07 | NA | 2.97 | 0.09 | 0.03 | 0.04 | 17.38 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Catalent, Inc. | Buy | $8.5B | 11.42% | 211.02 | -5.43% |
![]() Neurocrine Biosciences Inc. | Buy | $10.9B | -4.03% | 63.98 | 10.54% |
![]() Haleon Plc Spon Ads | Buy | $37.9B | 9.85% | 23.82 | 10.78% |
![]() Zoetis Inc. | Buy | $84.1B | 102.58% | 38.47 | 26.92% |
![]() Viatris Inc. | Hold | $13.0B | -39.47% | 7.07 | 11.88% |
Vanguard Group Inc
Capital World Investors
BlackRock Inc
HHG PLC
T. Rowe Price Investment Management,Inc.
Nomura Holdings Inc
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Organization | Catalent, Inc. |
Employees | 17800 |
CEO | Mr. John R. Chiminski |
Industry | Health Technology |
Federal Realty Investment Trust
$48.25
+1.54%
Alerian Mlp Etf Alps
$48.25
+1.54%
Ishares 0-5 Yr High Yield Corp Bond Etf
$48.25
+1.54%
Aurora Innovation Inc
$48.25
+1.54%
Exponent Inc
$48.25
+1.54%
Copa Holdings Sa
$48.25
+1.54%
Mercury Systems Inc
$48.25
+1.54%
Omnicell Inc
$48.25
+1.54%
First Trust Global Tactical Community Strategy Fund
$48.25
+1.54%